C4 TherapeuticsCCCC
Recorded

C4 Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration29 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Akash TewariGlobal Head of Biopharmaceutical Research

Good morning, everyone. It's still the morning. Day two of our Jefferies Global Healthcare Conference, and it's really been, again, a joy to see everyone, and so grateful for the attendance we see. My name's Akash Tewari. I am Global Head of our biotech and pharma research efforts within Jefferies, and we have the management team for C4 Therapeutics. Andrew's going to start a bit with some prepared remarks, but then we'll get into Q&A. Again, I will just say this, we picked up coverage on this this year, and when I think about established size of a market, and I cover Bristol, when I talk to Bristol, and they will wax poetic about the importance of CELMoDs, and then when I think about mid-cap companies that are pursuing the same strategy, the list is very short.

Akash TewariGlobal Head of Biopharmaceutical Research

I do think that is a very, very unique setup, and I do recommend you talk to them. Andrew, I'll hand it off to you.

Andrew HirschPresident and CEO

Great. Thank you, and that's a good introduction. Thanks for having us here. Before I begin, we'll be making forward-looking statements, and this is our disclaimer on that matter. C4 is a targeted protein degradation company, and we're really focused on really exploiting this novel modality. Our key focus right now in the clinic at least is on cemsidomide and multiple myeloma, as well as building a sustainable pipeline. We've got cemsidomide, which is our potential best-in-class cereblon-modulating protein degrader of IKZF1 and three. We are working to establish that as a backbone therapy in multiple myeloma.

Andrew HirschPresident and CEO

In addition, we have a discovery portfolio that is focused on inflammation, neuroinflammation, and neurodegeneration, in validated pathways, but against novel targets where degraders are important, as well as a number of platform collaborations that not only serve to expand the science of TPD, but really help in bringing some non-dilutive capital as part of our strategy. To that end, we are well-capitalized, where our runway is through the end of 2028, which brings us through and beyond some important points. What I'll focus on in my short remarks is cemsidomide. I think that's really where most of the discussion is, given the hybrid method of a presentation and Q&A. I think it's really important to start grounding in the mechanism of IKZF1/3 degradation. What is it, and what does it do?

Andrew HirschPresident and CEO

Way back when Celgene launched the IMiDs, no one actually knew what they did. They were developed in a way that I think was suboptimal in the sense that they are suboptimal by today's degradation standards. What is important about degrading IKZF1 and three is that it really leads to two outcomes. The first, you can see on the left panel, is it blocks the proliferation of plasma cells, which is really the root cause of multiple myeloma, so it has direct anti-myeloma activity. Importantly, it also activates the immune system, and that is going to be important when we think about the evolving landscape in multiple myeloma. What we know from lenalidomide and pomalidomide is that this mechanism really does serve as a backbone in multiple myeloma. It is used across all lines of treatment in multiple different combinations.

Andrew HirschPresident and CEO

As I mentioned, lenalidomide and pomalidomide are really suboptimal degraders. They are not very potent, and they are frankly not very selective, and that is why you hear a lot about the toxicity profile. The evolving landscape in myeloma is really critical as we think about the future and future development. One important aspect is immune-directed agents moving into earlier lines of treatment, both CAR-Ts and T-cell engagers. We think cemsidomide's profile actually sets it up very nicely to play in the new space, and I will show you why we think that. We ran a phase I first-in-human study, and this is a one-slide summary of the data. What is important is this study was done in the most heavily pre-treated patient population in late-line therapy. You can see that 75% of patients were post-BCMA, but also post-CAR-T and T-cell engager therapy.

Andrew HirschPresident and CEO

That is important because those are patients who, while we think we are curing this disease with these immune-directed agents, there is still an unmet need, they are still showing up, and they have still enrolled in our study. What is really dramatic is our safety profile is differentiated against BMS's next-gen degraders. You can see we have really had well-tolerated profile, and that has been coupled with, we think, really impressive anti-myeloma activity at our recommended phase II dose of 100 micrograms. You heard me right, that is micrograms. We had a 53% response rate with two MRD-negative CRs. Just to put that into context, in this late-line, heavily pre-treated population, it is something you do not normally see. Importantly, we saw a robust response at a dose level 1 below our recommended phase II dose at 75 micrograms, and an overall 36% response rate.

Andrew HirschPresident and CEO

We think that this is what really shows it is a best in class. It really has class-leading efficacy, anti-myeloma activity, with a sort of, we think, best-in-class safety profile. Combined together, that positions it well. I mentioned the second MOA, and this slide illustrates that. You can see across all doses, and what we are showing here is representative of the wealth of data we have on immune cell activation. The first two left panels are demonstrating our ability to activate T cells, and the consequence of that, you see increased IL-2 cytokine production across really all the dose levels that we studied, which is critically important as we think about combination strategies in the future. That leads to where the market opportunity is, and we think there is really two important opportunities.

Andrew HirschPresident and CEO

The first is, as these immune-directed agents move into earlier lines of treatment, patients are living longer, and that's great for patients, but these are not cures, despite what others in the field may start to talk about. We think what's happening there is two things. That's going to increase the population in the later line, fourth line plus, as those patients ultimately progress, and there is a need for an all-oral therapy for these patients. In addition, as we think about these agents moving into earlier lines of treatment, we think there's an opportunity to boost their activity and improve their duration by combining with an IKZF1/3 degrader. That's really where our development strategy is focused. Currently, we have two ongoing studies.

Andrew HirschPresident and CEO

The first is a phase II single-arm study we call MOMENTUM in late-line patients, and that is positioned as a potential for an accelerated approval. We're also running a phase I-B combination study with a BiTE, Pfizer's elranatamab, and that's in conjunction with a supply agreement with Pfizer. That study is going to support a pivotal study with the same combination, where we have another shot at accelerated approval with an MRD-negative CR. Importantly, we have a time-to-event endpoint that will serve as the confirmatory endpoint for both the accelerated approval in this second-line setting, but also for the late-line setting in the MOMENTUM study. Lastly, we're running a combination study with daratumumab and with carfilzomib as a way to establish broad combinability across the class, because as I mentioned, I think the profile that we demonstrated suggests that.

Andrew HirschPresident and CEO

Next year is setting up to be a really critical year. This year was one of execution, where we are aggressively enrolling our studies and generating data. Next year is really going to be data-rich. We expect to complete enrollment in the first quarter in the MOMENTUM study, with an initial response rate data readout in the second half. In the middle of the year, we expect to share data from all doses and cohorts studied in the elranatamab combination study in the middle of 2027, as well as start that combination study with a CD38 and a proteasome inhibitor. That's going to be pivotal in terms of setting up 2028, where, with the data supportive, we expect to submit by the end of the year for an NDA in that late-line setting and initiate that pivotal phase III study in combination.

Andrew HirschPresident and CEO

Drilling into the details here, MOMENTUM's a 100-patient study using the 100 microgram recommended phase II dose on a 14-day on, 14-day off schedule, and the primary endpoint is response rate. That trial is well underway, and we are confident that we're going to complete enrollment in the first quarter of next year. The phase I-B study, we started that earlier this year, and we've progressed that nicely. We started off one dose level below the recommended phase II dose at 75 micrograms. That has been declared safe, and we've now both escalated to 100 micrograms, the recommended phase II dose, as well as expanded to get additional patient experience at 75 micrograms.

Andrew HirschPresident and CEO

I think what is notable about that is when you look at other drugs in the class, when they have tried to do similar combinations, they have had to de-escalate from their recommended phase II dose, almost two to three doses below that. In contrast, we have been able to establish safety at one dose level below, and now working to establish safety at our recommended phase II dose. I think that speaks to the safety profile and its broad potential for combinability, really across the multiple myeloma landscape. I will end my prepared remarks just reinforcing IKZF1/3 degradation is really, it is a foundational mechanism in treating myeloma across all different lines and multiple combinations. The profile we have established suggests that it is a best in class in terms of both the combination of safety and efficacy.

Andrew HirschPresident and CEO

We are pursuing two distinct meaningful opportunities, both in the late line and in the second line or later. We have a strategic development plan that is set up to capture those opportunities with a data-rich 2027. With that, we will open it up to questions.

Akash TewariGlobal Head of Biopharmaceutical Research

Thank you. Really appreciate the prepared remarks.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day